Clean Watchlist Candidate

ATROVENT HFA

Respiratory · COPD, bronchospasm (anticholinergic bronchodilator)

ATROVENT HFA carries product patent, low complexity (0/5), and no linked clinical competition (0/5). The listed expiry window is approximately 43 months away. Low barriers across both dimensions — a cleaner first-screen candidate worth early IP attention.

Back to watchlist Contact us about this drug

LOE window

43months

to latest listed patent expiry (January 17, 2030)

Expiry attractiveness: 4/5

Patent profile

Substance patent (none)

Product / formulation patent (listed)

Use-code patent (none)

Patent count: 1

Complexity score: 0/5

Clinical competition

Score: 0/5

Active trials linked: 0

Phase 2/3 trials: 0

Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.

Drug overview

Active ingredient: IPRATROPIUM BROMIDE

Applicant (NDA holder): BOEHRINGER INGELHEIM PHARMACEUTICALS INC

Confidence: Medium

Market context

Therapeutic area: Respiratory

Indication: COPD, bronchospasm (anticholinergic bronchodilator)

U.S. market size (est.)< $100M

Estimated U.S. net sales tier. Verify current figures before commercial diligence.